Recent Press Releases

Bayer Receives Approval for Nexavar® (sorafenib) in Japan for Treatment of Differentiated Thyroid Cancer

Bayer Receives Approval for Nexavar® (sorafenib) in Japan for Treatment of Differentiated Thyroid Cancer Berlin, June 20, 2014 – Bayer HealthCare announced today that the Ministry of...

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT ANY FIRM OFFER WI

LONDON, June 19, 2014 -- AbbVie Inc. ("AbbVie") notes the recent press speculation and confirms it made an indicative approach to Shire plc ("Shire") with a merger proposal which...

Teva Reaches Settlement in ProAir® HFA Patent Case

Teva Reaches Settlement in ProAir® HFA Patent Case JERUSALEM, Jun 20, 2014 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. TEVA +0.41% announced that it has reached a settlement with...

Clinigen Group's Peter George Wins Chief Executive of the Year Award at the European Mediscience Awards 2014

Clinigen Group's Peter George Wins Chief Executive of the Year Award at the European Mediscience Awards 2014 Burton-on-Trent, UK – 20 June 2014 – Clinigen Group (AIM: CLIN), the...

Specialty Pharmaceutical Management Consulting Firm Viscadia Hires Brandon Kocher

Specialty Pharmaceutical Management Consulting Firm Viscadia Hires Brandon Kocher Washington D.C. – June 17, 2014 – Specialty pharmaceutical management consulting firm Viscadia Inc. is...

ERYtech Pharma Appoints Two New Independent Board Members

ERYtech Pharma Appoints Two New Independent Board Members ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative 'tumor...

Horizon Pharma Announces Robert J. De Vaere To Retire And Names Paul W. Hoelscher Chief Financial Officer

Horizon Pharma Announces Robert J. De Vaere To Retire And Names Paul W. Hoelscher Chief Financial Officer DEERFIELD, IL--(Marketwired - June 18, 2014) - Horizon Pharma, Inc. (NASDAQ: HZNP) today...

Valeant Commences Exchange Offer For Allergan

06/18/2014 LAVAL, Quebec, June 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange...

Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit

Actavis Confirms District Court Ruling In Generic Exelon® Patch Patent Suit DUBLIN, June 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for...

Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa'

Cipla collaborates with Hetero to launch its second biosimilar drug 'Darbepoetin alfa' ~Patients with chronic kidney disease and anaemia set to gain~ India, Mumbai, 19th June 2014: Cipla, a global...

UK NICE to hold oral appeal hearing for FIRMAGON® (degarelix) for the treatment of advanced hormone-dependent prostate cancer

UK NICE to hold oral appeal hearing for FIRMAGON® (degarelix) for the treatment of advanced hormone-dependent prostate cancer WEST DRAYTON, England, 17 June, 2014 – Ferring Pharmaceuticals...

Forest Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR®

Forest Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR® NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S Food and Drug...

Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day

Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day New Novartis focused on three leading businesses with innovation power and global scale Pharmaceuticals...

PHT streamlines clinical trials with Windows 8.1 tablets

Provider of patient-driven eData Systems will run data collection system on Dell Venue 11 Pro tablets with Windows 8.1.

REDMOND, Wash.

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

-- No additional clinical trials requested by the FDA

RIDGEFIELD, Conn. and INDIANAPOLIS,

FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)

FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) CHESHIRE, Conn., Jun 17, 2014 (BUSINESS WIRE) -- Alexion Pharmaceuticals ALXN...

Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk

Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk LAVAL, Quebec, Jun 16, 2014 (Canada NewsWire via COMTEX) -- Valeant Pharmaceuticals International, Inc. VRX -1.55% CA:VRX...

Bayer's gadavist injection gets FDA approval as MRI contrast agent

Bayer's gadavist injection gets FDA approval as MRI contrast agent Bayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication for Gadavist...

Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials Phase III data from two clinical...